We are live on ! Find out more
CC

Commodore Capital Portfolio holdings

AUM $1.73B
1-Year Est. Return 298.96%
This Fund
S&P 500
This Quarter Est. Return
+39.05%
1 Year Est. Return
+298.96%
3 Year Est. Return
+2,048.53%
5 Year Est. Return
+6,668.48%
10 Year Est. Return
–
AUM
$1.73B
AUM Growth
+$226M
Cap. Flow
-$19.1M
Cap. Flow %
-1.1%
Top 10 Hldgs %
61.35%
Holding
45
New
12
Increased
7
Reduced
6
Closed
9

Top Buys

Rank Stock Value
1
DMRA
Damora Therapeutics, Inc. Ordinary Shares
DMRA
+$49.8M
2
EYPT icon
EyePoint Inc
EYPT
+$42.2M
3
ERAS icon
Erasca
ERAS
+$37.5M
4
CRVS icon
Corvus Pharmaceuticals
CRVS
+$36M
5
NUVL
Nuvalent
NUVL
+$28.9M

Top Sells

Rank Stock Value
1
TERN
Terns Pharmaceuticals
TERN
+$59.6M
2
ORKA
Oruka Therapeutics
ORKA
+$53.1M
3
XENE icon
Xenon Pharmaceuticals
XENE
+$44.9M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$39.3M
5
ELVN icon
Enliven Therapeutics
ELVN
+$39.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.71%
2 Financials 0.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RLAY icon
1
Relay Therapeutics
RLAY
$4.02B
$169M 9.79%
17,000,000
– –
ALKS icon
2
Alkermes
ALKS
$8.82B
$149M 8.59%
4,200,000
+650,000
+18% +$20.2M
ELVN icon
3
Enliven Therapeutics
ELVN
$3.78B
$128M 7.43%
3,275,000
-1,417,809
-30% -$39.3M
COGT icon
4
Cogent Biosciences
COGT
$6.79B
$111M 6.43%
2,888,007
+691,162
+31% +$25.5M
SYRE icon
5
Spyre Therapeutics
SYRE
$8.87B
$96.5M 5.58%
1,912,380
-475,865
-20% -$17.9M
TYRA icon
6
Tyra Biosciences
TYRA
$1.82B
$94.8M 5.48%
2,475,000
-900,000
-27% -$29.1M
CLDX icon
7
Celldex Therapeutics
CLDX
$2.77B
$85.5M 4.95%
2,696,616
+131,616
+5% +$3.59M
NUVL
8
DELISTED
Nuvalent
NUVL
$85.4M 4.94%
833,600
+283,600
+52% +$28.9M
AMLX icon
9
Amylyx Pharmaceuticals
AMLX
$2.05B
$78.5M 4.54%
5,650,000
– –
KYMR icon
10
Kymera Therapeutics
KYMR
$9.1B
$62.5M 3.61%
750,000
– –
ANRO icon
11
Alto Neuroscience
ANRO
$1.04B
$61.2M 3.54%
2,723,196
+900,000
+49% +$16.7M
PHVS icon
12
Pharvaris
PHVS
$2.39B
$54.2M 3.14%
1,918,970
+29,525
+2% +$789K
ERAS icon
13
Erasca
ERAS
$6.63B
$51.4M 2.97%
+3,175,000
New +$37.5M
DMRA
14
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.77B
$50.2M 2.91%
+1,939,000
New +$49.8M
XENE icon
15
Xenon Pharmaceuticals
XENE
$6.32B
$48M 2.78%
825,000
-975,000
-54% -$44.9M
DFTX
16
Definium Therapeutics
DFTX
$5.73B
$37.8M 2.19%
2,000,000
– –
LBRX
17
LB Pharmaceuticals
LBRX
$1B
$37M 2.14%
1,500,000
– –
EYPT icon
18
EyePoint Inc
EYPT
$1.02B
$36.4M 2.11%
+2,825,000
New +$42.2M
NRIX icon
19
Nurix Therapeutics
NRIX
$2.43B
$35.3M 2.04%
2,275,000
– –
CRVS icon
20
Corvus Pharmaceuticals
CRVS
$1.1B
$33M 1.91%
+2,258,735
New +$36M
ASMB icon
21
Assembly Biosciences
ASMB
$506M
$27.8M 1.61%
1,000,000
– –
CATX icon
22
Perspective Therapeutics
CATX
$332M
$26.4M 1.53%
+6,336,782
New +$26.8M
SLNO
23
DELISTED
Soleno Therapeutics
SLNO
$21.8M 1.26%
652,432
-547,568
-46% -$21.5M
OCUL icon
24
Ocular Therapeutix
OCUL
$1.86B
$21.8M 1.26%
+2,575,000
New +$24.5M
IPSC icon
25
Century Therapeutics
IPSC
$381M
$19.7M 1.14%
+8,695,652
New +$18.3M
1
2

Similar funds

RIA
Regal Investment Advisors Kentwood, Michigan $1.73B AUM 17.74% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.73B AUM 17.28% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
ESBC
E.S. Barr & Co Lexington, Kentucky $1.72B AUM 12.69% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $1.72B AUM 48.78% 1-Year Est. Return
WJA
Willis Johnson & Associates Houston, Texas $1.72B AUM 16.93% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Commodore Capital's Q1 2026 Portfolio in Review

As of Q1 2026, Commodore Capital held 45 positions worth $1.73B, up 15% from $1.5B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Commodore Capital's Q1 2026 filing shows 12 new, 7 increased, 6 reduced and 9 closed positions. Its largest new stake was Damora Therapeutics, Inc. Ordinary Shares: 1,939,000 shares worth $50.2M. The largest sale was Terns Pharmaceuticals, an estimated $59.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

  • Commodore Capital's largest Q1 2026 buy was Damora Therapeutics, Inc. Ordinary Shares: 1,939,000 shares worth $50.2M.
  • Commodore Capital added most to Nuvalent in Q1 2026, an estimated $28.9M increase.
  • Commodore Capital's biggest Q1 2026 reduction was Xenon Pharmaceuticals, cutting an estimated $44.9M.
  • Commodore Capital fully exited Terns Pharmaceuticals in Q1 2026, selling an estimated $59.6M.
  • Commodore Capital's ten largest holdings make up 61% of its $1.73B portfolio in Q1 2026.
  • Commodore Capital opened 12 new positions and closed 9 in Q1 2026.
  • Commodore Capital's portfolio value rose 15% quarter-over-quarter to $1.73B.

Based on Commodore Capital's 13F filing for Q1 2026, filed 15 May 2026.